BCAL Diagnostics (ASX:BDX) EPS (Basic) : A$-0.02 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics EPS (Basic)?

BCAL Diagnostics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was A$-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

BCAL Diagnostics's EPS (Diluted) for the six months ended in Dec. 2023 was A$-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

BCAL Diagnostics's EPS without NRI for the six months ended in Dec. 2023 was A$-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

BCAL Diagnostics EPS (Basic) Historical Data

The historical data trend for BCAL Diagnostics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics EPS (Basic) Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

EPS (Basic)

-0.02

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial			-0.01	-0.01	-0.01	-0.01	-0.01

BCAL Diagnostics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

BCAL Diagnostics's Basic EPS for the fiscal year that ended in Jun. 2023 is calculated as

Basic EPS (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.062	-	0)	/	210.903
	=	-0.02

BCAL Diagnostics's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.407	-	0)	/	231.397
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02

BCAL Diagnostics (ASX:BDX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BCAL Diagnostics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.